|
10 Feb 2020 |
Bayer announces Phase III trials with new aflibercept 8mg formulation
|
|
10 Feb 2020 |
Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
|
|
09 Feb 2020 |
EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy
|
|
07 Feb 2020 |
Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer
|
|
06 Feb 2020 |
Scholar Rock Presents Data for SRK-015 at the SMA Europe 2nd International Scientific Congress
|
|
06 Feb 2020 |
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies
|
|
06 Feb 2020 |
Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic
|
|
06 Feb 2020 |
CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers
|
|
04 Feb 2020 |
Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates (ADCs) to Treat Humoral Immuno-Suppressed Cancers
|
|
04 Feb 2020 |
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
|
|
03 Feb 2020 |
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
|
|
03 Feb 2020 |
United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint
|
|
02 Feb 2020 |
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
|
|
02 Feb 2020 |
Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
|
30 Jan 2020 |
F-star Therapeutics Announces FDA Acceptance of IND Application for FS120
|
|
28 Jan 2020 |
FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
|
|
28 Jan 2020 |
Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept in Pre-Clinical Study
|
|
28 Jan 2020 |
Leronlimab Under Evaluation for Potential Treatment of Coronavirus
|
|
28 Jan 2020 |
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
|
|
28 Jan 2020 |
AbCellera Is Mobilizing a Response to the Novel Coronavirus Outbreak as Part of Its DARPA P3 Program
|
|
28 Jan 2020 |
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
|
|
28 Jan 2020 |
Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
|
|
27 Jan 2020 |
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
|
|
27 Jan 2020 |
Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
|
|
27 Jan 2020 |
AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan
|
